GE Healthcare and Swedish biopharmaceutical company Affibody are collaborating on the development of a HER2-targeted PET imaging agent for patients with breast or gastric cancer.
Clinical trials are scheduled to begin later this year, according to the companies. These trials will investigate the confirmation of HER2 (human epidermal growth factor receptor 2) status in patients with breast cancer recurrence to determine if HER2 status changes over time. The studies will also monitor the therapy results of patients with metastatic breast cancer receiving anti-HER2 treatments and help resolve indeterminate HER2 tests.
